Abstract 444P
Background
High-dose cytarabine (HDAC) is used to treat hematologic malignancies. Eye disorders are common side effects caused by cytarabine (AraC) being transported from the blood into tear fluid. In our institution, four times a day (FM4) or six times a day (FM6) of 0.1% fluorometholone eye drops are used to prevent AraC-induced eye disorders. In this study, we investigated the prophylactic effects of FM6 or FM4 to prevent AraC-induced eye disorders retrospectively.
Methods
We targeted the patients who were hospitalized and administered with HDAC twice a day at a dose of 1 g/m2 or more between April 2011 and March 2018. The patients received 0.1% fluorometholone eye drops in a both eyes from the start of HDAC dose to 48 hours after the end of HDAC dose. We investigated the incidence of eye disorders or grade based on the medical records from the start of HDAC dose until 7 days after the end of HDAC dose, retrospectively.
Results
There were 36 patients of FM4 and 44 of FM6 for prevention of AraC-induced eye disorders, respectivity. The incidence of eye disorders was 6 (16.7%) in FM4 and 7 (15.9%) in FM6. No Grade 3 eye disorders occurred in both groups. The number of courses of the eye disorder appeared for FM4 and FM6 were 1 and 2 courses. In addition, the median of AraC cumulative dose at the time of the eye disorders appeared for FM4 and FM6 was 10 (4-20) g/m2 and 20 (6-42) g/m2.
Conclusions
There is no difference in preventive effect between FM4 and FM6 for AraC-induced eye disorders. Further, FM4 is considered useful and a convenient method for the prevention of AraC-induced eye disorders.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
133P - Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
134P - Identification, development and validation of a circulating miRNA-based diagnostic signature for early detection of gastric cancer
Presenter: Daisuke Izumi
Session: Poster display session
Resources:
Abstract
135P - The promising key genes associated with tumour microenvironment and prognosis of hepatocellular carcinoma
Presenter: Jing Fang
Session: Poster display session
Resources:
Abstract
136P - Helicobacter pylori-positive gastric diffuse large B-cell lymphoma: A subset with distinct prognostic features
Presenter: Yuan Cheng
Session: Poster display session
Resources:
Abstract
137P - Significant benefit of pyrotinib combined with SHR6390 in patients with multiline-resistant HER2-positive advanced gastric cancer
Presenter: Zuhua Chen
Session: Poster display session
Resources:
Abstract
138P - Incidence of supracarinal lymph node positivity in operated cases of total esophagectomy: Short term results from a tertiary cancer centre
Presenter: Akhil Palod
Session: Poster display session
Resources:
Abstract
139P - Prognostic usefulness of advanced lung cancer inflammation index in locally-advanced pancreatic carcinoma patients treated with radical chemoradiotherapy
Presenter: Ayberk Besen
Session: Poster display session
Resources:
Abstract
140P - Pancreaticoduodenectomy versus combined neoadjuvant chemotherapy and pancreaticoduodenectomy: Survival patterns among patients with stage II & III periampullary carcinoma
Presenter: Mai Abdelkader
Session: Poster display session
Resources:
Abstract
141P - A 13-gene signature of DNA repair predicts prognosis in gastric cancer patients
Presenter: Jinjia Chang
Session: Poster display session
Resources:
Abstract
142P - Relation between Interleukin -4 (590C/T) gene polymorphism and hepatocellular carcinoma risk in HBV and HCV patients
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract